Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed EBITDA Margin for 6 consecutive years, with 63.87% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 209.0% to 63.87% in Q3 2025 year-over-year; TTM through Sep 2025 was 87.88%, a 454.0% decrease, with the full-year FY2024 number at 70.33%, up 5065.0% from a year prior.
  • EBITDA Margin was 63.87% for Q3 2025 at Vivos Therapeutics, up from 119.42% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 200.48% in Q4 2021 to a low of 176.7% in Q1 2022.
  • A 5-year average of 94.77% and a median of 116.65% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 38985bps in 2021, then plummeted -35397bps in 2022.
  • Vivos Therapeutics' EBITDA Margin stood at 200.48% in 2021, then plummeted by -177bps to 153.49% in 2022, then increased by 18bps to 125.74% in 2023, then skyrocketed by 44bps to 70.47% in 2024, then increased by 9bps to 63.87% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBITDA Margin are 63.87% (Q3 2025), 119.42% (Q2 2025), and 123.28% (Q1 2025).